L. Daniel Browne
2014
In 2014, L. Daniel Browne earned a total compensation of $9M as President and Chief Executive Officer at Revance Therapeutics, a 306% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $158,323 |
|---|---|
| Option Awards | $5,207,855 |
| Salary | $452,352 |
| Stock Awards | $3,093,120 |
| Other | $44,003 |
| Total | $8,955,653 |
Browne received $5.2M in option awards, accounting for 58% of the total pay in 2014.
Browne also received $158.3K in non-equity incentive plan, $452.4K in salary, $3.1M in stock awards and $44K in other compensation.
Rankings
In 2014, L. Daniel Browne's compensation ranked 633rd out of 13,032 executives tracked by ExecPay. In other words, Browne earned more than 95.1% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 633 out of 13,032 | 95th |
Division Manufacturing | 226 out of 4,965 | 95th |
Major group Chemicals And Allied Products | 73 out of 1,690 | 96th |
Industry group Drugs | 56 out of 1,369 | 96th |
Industry Pharmaceutical Preparations | 53 out of 1,042 | 95th |
Source: SEC filing on March 18, 2016.
Browne's colleagues
We found three more compensation records of executives who worked with L. Daniel Browne at Revance Therapeutics in 2014.